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Abstract 
The emergence of induced pluripotent stem cell (iPSC) technology paves the way to generate 
large numbers of patient-specific endothelial cells (EC) that can be potentially delivered for 
regenerative medicine in patients with cardiovascular disease. In the last decade, numerous 
protocols that differentiate EC from iPSC have been developed by many groups. In this review 
we will discuss several common strategies that have been optimized for human iPSC-EC (hiPSC-
EC) differentiation and subsequent studies that have evaluated the potential of hiPSC-EC as a 
cell therapy or as a tool in disease modeling. In addition, we will emphasize the importance of 
using in vivo vessel forming ability and in vitro clonogenic colony forming potential as a gold 
standard with which to evaluate the quality of hiPSC-EC derived from various protocols.  
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iPSC   Induced pluripotent stem cell 
TALEN   Transcription activator-like effector nucleases 
 
 
 
 
 
 
 
 
 
Introduction 
Cardiovascular diseases (CVD), which are often triggered by endothelial dysfunction, represent 
one of the leading causes of mortality in the world. In 2015, over 17 million deaths, which 
represents 31% of global deaths, were caused by CVD.1 The treatment of CVD through 
endothelial replacement is hindered by the lack of methods to isolate sufficient numbers of 
functionally normal autologous endothelial cells (EC) for transplantation and our limited 
understanding of how endogenous endothelial cells become dysfunctional during development of 
various cardiovascular diseases. The innovation of human induced pluripotent stem cells (hiPSC), 
cells that are reprogrammed from somatic cells to an embryonic stem cell (ESC)-like pluripotent 
state,2, 3 presents an opportunity for us to generate large numbers of patient-specific EC that can 
be used for transplantation, drug screening, or studies to probe the mechanisms for endothelial 
dysfunction in certain disease states. Here we will retrospectively catalog and survey the methods 
developed by various groups to differentiate hiPSC to EC. We will focus on several common 
topics shared by all the papers, including the strategies for hiPSC-EC differentiation, the 
importance of functional and phenotypic testing of the hiPSC for quality control, and the potential 
applications of hiPSC-EC as a cell therapy for human subjects. Articles discussing human ESC 
derived EC derivation, PSC-EC differentiation from non-human species, and the development of 
other cell types through EC intermediates, like hemogenic endothelium, will not be covered here 
and discussions on these topics can be found elsewhere.4-7 
 
Strategies for hiPSC-EC differentiation 
Methods to differentiate EC from hiPSC can be divided into 3 general categories: 1) Stromal cell 
co-culture, 2) Embryoid body (EB) differentiation, and 3) Feeder-free monolayer differentiation 
(Figure 1).  
The methods to differentiate EC from hiPSC by co-culture with stromal cells, usually 
murine bone marrow derived stromal cell lines like OP9 or M10B2, were mainly used in some of 
the earliest studies in the field.8-11 This is an undirected differentiation strategy in which the 
frequency of differentiated EC is generally low and the EC produced were often mixed with other 
cell types including hematopoietic cells,8 smooth muscle cells,9, 10 and inevitably murine stromal 
cells. Thus this method is not ideal for the generation of a large number of EC for regenerative 
medicine applications.     
EB methods rely on the spontaneous differentiation of aggregated hiPSC in the context of 
a self-assembled three dimensional (3D) structure. The development of many cell lineages in EB 
seems to recapitulate the progression of early embryonic development. Thus, the differentiation 
of EB is also not a fully controlled process and single step long term (10-12 days) EB 
differentiation method usually gives rise to a low EC yield.12-22  Many researchers differentiate EB 
for a shorter period (3-6 days), usually in the presence of added growth factors that promote 
mesoderm and/or endothelial lineage specification including BMP4, Activin A, bFGF, and VEGF. 
At this stage, mesoderm and immature endothelial cells are robustly induced. These cells, 
together with other differentiated cell types from EB,23-34 or enriched by fluorescence-activated 
cell sorting (FACS) or magnetic-activated cell sorting (MACS) via the use of monoclonal 
antibodies that identify the expression of mesodermal and/or endothelial cell surface markers like 
CD309 (KDR),35-40 CD34,37 and CD31 (PECAM-1),35 are then expanded/enriched in monolayer 
culture conditions that favors the growth of EC. Some protocols developed using this strategy 
have differentiated functional EC from human hiPSC that exhibited the ability to form in vivo 
vessels.24, 25, 29, 34, 36, 38 
The final general strategy is to culture a monolayer of hiPSC on a matrix coated culture 
plate and treat them with different molecules or growth factors in a timed fashion to dictate the 
progressive differentiation from PSC to mesoderm and finally towards the EC lineage. To date, 
the protocols that have led to some of the highest EC yields were developed using this general 
strategy.25, 41, 42 Most protocols using this strategy can be divided into a mesoderm differentiation 
phase and an endothelial differentiation phase. Some protocols will change the culture medium 
and growth factors between the mesoderm and endothelial stages, but without disturbing the 
cultured cells,25, 41-62 while others purify the mesoderm cells or immature EC through detection of 
cells expressing KDR,54, 63-65 CD34,66-68 MESP1,69 or CD3167 between these two phases. Once 
purified the cell populations are further optimized to generate homogenous EC preparations.  
Manipulating the signaling pathways that specify mesoderm differentiation from the hiPSC 
is common to these monolayer differentiation systems. Thus, growth factors like Activin A, BMP4, 
and bFGF are commonly used. GSK-3 inhibitors like CHIR99021 and BIO are also frequently 
added to the medium during this phase to promote the canonical Wnt signaling pathway which 
stimulates the differentiation of the hiPSC derived mesoderm towards the endothelial lineage,25, 
30, 37, 43, 44, 47, 48, 50, 55, 56, 59, 60, 62, 63, 66, 67, 69 although the effectiveness of GSK-3 inhibition in enhancing 
EC specification has been questioned.63 Endothelial lineage cells are expanded in the second 
phase. VEGF is the most common growth factor that is used during this phase. Inhibition of the 
TGF-β signaling pathway has been reported to be crucial for promoting the endothelial 
specification from mesoderm cells and the maintenance of EC (to avoid endothelial to 
mesenchymal transition) in some protocols.30 Thus SB431542, an inhibitor of TGF-β signaling 
pathway, has often been included in many protocols to maintain and expand EC in the second 
phase.30, 43, 44, 49, 51, 57, 58, 61  
To further improve the differentiation efficiency of EC from hiPSC, a deeper understanding 
of the development of the EC lineage is required. Researchers are trying to discover new signaling 
pathways or develop novel culture conditions to improved EC differentiation. Park et al.68 have 
reported that inhibition of the MEK/ERK pathway by addition of the inhibitor PD98059 during the 
mesoderm induction stage increased the production of EC. However, in Lian et al.’s study,66 
addition of the MEK inhibitor PD0325901 decreased the production of CD31+CD34+ EC. Sahara 
et al.25 reported that inhibition of the Notch signaling pathway during the late phase of EC 
differentiation, either by transcript knockdown or by addition of the γ-secretase inhibitor DAPT, 
led to a higher efficiency of EC production. Liang et al.,51 showed that miR-495 could promote the 
production of EC from hiPSC and improve the angiogenic potential, as well as, the in vivo vessel 
forming ability of hiPSC-EC via interacting with vascular endothelial zinc finger 1. Cochrane and 
colleagues reported that the RNA binding protein Quaking isoform 5 stabilizes STAT3 and 
activates the expression of KDR, thus promoting EC differentiation and angiogenesis functions.36 
In addition, cyclic adenosine monophosphate (cAMP) has also been added in the EC phase of 
differentiation to enhance EC enrichment.54, 64 Zhang et al.70 promoted the differentiation of hiPSC 
into EC in a 3D porous fibrin scaffold and 45% of hiPSC were differentiated to EC. They reasoned 
that the higher EC differentiation efficiency was due to the 3D surface tension provided by the 
scaffold.70 Recently, Zhang et al.69 suspended hiPSC derived MESP1+ mesodermal cells in a 3D 
biodegradable gelatin based scaffold and observed more enrichment of the CD31+ EC population 
than from hiPSC-derived mesoderm cells grown in 2D cultures. 
Because hiPSC-EC are differentiated in vitro, they are not exposed to the fluid flow, 
pulsatile pressure, or specific tissue microenvironments that impact endogenous EC 
differentiation in vivo and thus, hiPSC-EC display an indeterminate phenotype; neither committed 
fully to an arterial or a venous fate.29 Rufaihah et al.29 discovered that hiPSC-EC derived using 
the EB differentiation method possess heterogeneous arterial, venous and lymphatic marker 
expression and they could be directed to differentiate toward the arterial,29, 31, 71 lymphatic29, 72 or 
venous29 EC lineages through the manipulation of culture conditions. HiPSC-EC have also been 
induced in various culture conditions that mimic specific tissue microenvironments to induce 
tissue specific EC phenotypes. The most extensively studied tissue specific hiPSC-EC phenotype 
is brain microvascular EC (BEC).64, 73-85 Corneal-86 and choroidal-87 like EC have also been 
differentiated from hiPSC. However, at this time none of these in vitro induced tissue specific EC 
has been validated extensively in vivo. Thus, whether these cells genuinely represent their in vivo 
counterparts and how long can they keep their tissue-specific phenotype in vivo remains 
unknown. 
 
Quality controls for hiPSC-EC  
While EC differentiated from hiPSC through numerous methods exhibit some common traits 
including, expression of a panel of EC cell surface markers, in vitro 2D capillary-like tube forming 
potential, and ability to uptake low-density lipoprotein (LDL) (Figure 2), these properties alone 
may be insufficient to assess the function of EC to generate blood vessels in vivo. Indeed, many 
cell types other than EC, like some myeloid lineage hematopoietic cells, can also express EC 
markers and exhibit tube formation and LDL binding phenotypes in vitro88, 89, whereas only bona 
fide EC form stable, functional blood vessel networks that inosculate with host vasculature upon 
transplantation.88 Thus, in vivo vessel forming potential should be a necessary assay of EC 
derived from hiPSC (Figure 2). One commonly used in vivo vessel forming assay is to implant 
cells within a matrix and deliver the matrix into the subcutaneous space or prepared tissue. In this 
assay, donor test EC are loaded into a 3D matrix comprised of collagen,41, 42 Matrigel,16, 19, 24, 25, 29, 
34, 36, 38, 40, 68, 90 fibrinogen,47 or a degradable hydrogel61 for transplantation. The matrices can be 
retrieved from the animals at different time points post-implantation to assess the extent of donor 
derived vessels, determination of whether or not the donor-derived vessels have inosculated with 
the host vasculature, and the length of time that the donor cells persist. This method is 
reproducible (once preliminary studies are completed to optimize the matrix composition, donor 
cell number, and strain of mice implanted and attention paid to ongoing reagent quality control), 
straightforward to perform, and thus, is suitable as a standard test to compare the quality of 
hiPSC-EC derived from different methods of production. Other more invasive methods to assess 
endothelial functions of hiPSC-EC have also been tested including, experimental hind limb 
ischemia,22-24, 42, 68, 69 myocardial infarction,24, 25, 51 wound healing16, 65, 72 and retinopathy34, 42 
models. Though these models are important for testing the therapeutic potential of hiPSC-EC, 
these interventional models are influenced by a host of variables including animal strain, sex, age, 
skill of the technicians, and whether or not the host animals are wild type or carry transgenic 
modifications. Moreover, in these models, the beneficial effect of the donor cell populations can 
be conveyed via indirect mechanisms in addition to effects derived from the direct formation of 
donor derived vessels.89 For example, cell types like hematopoietic cells and mesenchymal 
lineage cells, which are common co-products of many hiPSC-EC differentiation protocols, can 
also improve blood perfusion by indirect means via secreting angiocrine factors or stabilizing 
newly formed vessels.41, 89, 91 However, these non-EC cell types do not integrate into newly-formed 
blood vessels.89, 92, 93 Thus, in their potential clinical applications, whether they can provide long-
term protection to the blood vessels to the hosts, especially those who have EC with compromised 
proliferative potential,42 is questionable. For this reason, whenever these animal disease models 
are used for testing the function of hiPSC-EC, it is necessary to validate the long-term contribution 
of donor EC to the host blood vessels. Finally, inclusion of a standard source of primary human 
EC, such as human umbilical cord venous endothelial cells (HUVEC) or umbilical cord blood 
endothelial colony forming cells (ECFC) as a control for comparison to the test hiPSC-EC 
population in the implant assay provides important information as to how similar the test EC are 
functioning in vivo. Recently, in vitro 3D vasculogenesis/angiogenesis models that mimic the 
vessel forming process in vivo have been applied to test hiPSC-EC.34, 48, 57, 61, 62, 94, 95 In these 
studies, hiPSC-EC are embedded into 3D matrix made with fibrin61, collagen,34, 48, hyaluronic acid 
hydrogel,57 or poly(ethylene glycol) (PEG) hydrogels62, 94, 95 under static conditions34, 48, 57, 61, 62, 94, 
95 or flow conditions in microfluidic chips95 and the hiPSC-EC self-assembled into lumenized blood 
vessel-like structures.34, 48, 57, 61, 62, 94, 95 Transcriptome analyses showed that the gene expression 
pattern of hiPSC-EC cultured in such conditions are more consistent with that of EC during the in 
vivo vasculogenesis/angiogenesis process compared to cells cultured in vitro under static 
conditions.62, 95 Thus, in vitro 3D tube forming assays can be used for pre-screening of functional 
hiPSC-EC before in vivo testing (Figure 2). 
Another property of EC that is often neglected in assessing the quality of the EC derived 
from the various differentiation protocols is a quantitative measure of the proliferative potential of 
the hiPSC-EC (Figure 2). Evidence from both human and other species has shown that vascular 
EC are heterogeneous with respect to proliferative potential. Over the past decade, it has been 
reported that among the EC derived from blood vessels or within the bloodstream, some EC 
display the potential to clonally propagate in vitro, self-renew in vivo, and give rise to more EC 
during vessel growth or regeneration.96-103 Those EC identified by their potential to form 
endothelial colonies in vitro96-102 have been called outgrowth EC or endothelial colony forming 
cells (ECFC).98, 104 A single high proliferative potential ECFC can give rise to a colony that contains 
over 10,000 EC progeny, which may include more progenitors with equal or less proliferative 
potential,97, 98 while more mature EC may not be capable of dividing or giving rise to only a few 
progeny. Indeed, hiPSC-EC derived from many protocols have displayed restricted proliferative 
potential and either undergo senescence within 5-8 passages or undergo endothelial to 
mesenchymal transition (EMT). To date, only a few studies have compared the proliferative 
potential of different hiPSC-EC fractions and tried to enrich the population of hiPSC-EC with high 
proliferative potential.25, 41, 42 Two studies have compared the colony forming potential of different 
EC fractions at a single cell level.25, 42 Prasain et al.42 reported that after 12 days of hiPSC 
differentiation, EC could be discriminated into 2 groups based upon the expression of Neuropilin1 
(NRP1), a co-receptor of VEGF and CD31. Only NRP1+CD31+ hiPSC-EC gave rise to ECFC that 
contained high proliferative potential when plated in a single cell assay and showed overwhelming 
superior in vivo vessel forming potential after transplantation than the NRP1-CD31+ population.42 
Using this culture strategy, hiPSC-EC derived from this protocol can be propagated for up to 18 
passages and the hiPSC:EC ratio reached 1:100,000,000 within an 2-3 month period.42 In the 
same year, Sahara et al. reported25 that among all hiPSC-EC populations, CD34+CD14- EC 
displayed the highest single cell EC colony forming potential and in vitro tube-forming ability. EC 
derived from this population also exhibited in vivo vessel forming potential in Matrigel plug and 
myocardial infarction models.25 In addition, Samuel et al.41 discovered and reported, that 
CD34+NRP1+KDR+ EC displayed the highest proliferative potential among all hiPSC-EC tested in 
a specific protocol. EC from this fraction could be expanded for 15 passages and showed long-
term in vivo vessel forming potential.41 However, unlike hiPSC-EC derived from the Prasain42 or 
Sahara25 methods, hiPSC-EC derived from the Samuel et al.41 protocol could not form in vivo 
vessels alone without the co-transplantation of mesenchymal cells.41 Thus, whether these cell 
populations represent a similar cell type among all three reports is still elusive. Further efforts to 
specifically enrich and expand high proliferative ECFC, or an equivalent population, gain a deeper 
understanding of the mechanisms of EC self-renewal and proliferation, develop new culture 
strategies to maintain high proliferative ECFC fractions, and to compare and contrast specific 
ECFC populations derived from hiPSC with EC present in the vasculature of human subjects will 
be important areas for investigation.  
 
The source of pluripotent cells and hiPSC-EC phenotype 
While hiPSC have similar properties and differentiation potential with EC, evidence has emerged 
that hiPSC possess slightly different gene expression and epigenetic patterns due to their gain or 
loss of epigenetic memory from their somatic sourced material during the reprogramming 
process.105-108 Thus, to safely apply hiPSC-EC for cell therapy or mechanistic studies, it is crucial 
to understand the differences among EC derived from hESC and those hiPSC derived from 
various somatic cell origins.   
Many studies that differentiated EC from hiPSC line have also tested their protocols with 
ESC lines and some researchers compared the phenotype and function of EC derived from both 
sources. With a few exceptions,27 most authors have agreed that hiPSC-EC generally exhibit 
comparable EC phenotypes and functions with ESC derived EC.19, 20, 22, 24, 25, 40, 42-44, 59, 65 Three 
studies compared the transcriptome between multiple ESC-EC and hiPSC-EC lines differentiated 
using the EB differentiation method and found that gene expression profiles between ESC-EC 
and hiPSC-EC showed some variance but, overall were very similar.19, 34, 40  
To date, most differentiation protocols have focused on the use of hiPSC derived from 
fibroblasts, a mature cell type. Some studies compared the EC differentiation potential from hiPSC 
derived from fibroblasts and other cell sources, include some immature cell populations like cord 
blood34 or peripheral blood109 mononuclear cells, bone marrow mesenchymal stem cells (BM-
MSC)33 and dental pulp cells,24 or EC like human umbilical cord vein endothelial cells (HUVEC)17, 
28 and cord blood ECFC.43, 44 The conclusions from those studies have provided multiple different 
interpretations of the importance of the source of cells with respect to derivation of hiPSC-EC. 
While some reports suggest immature cells or EC derived iPSC have a higher tendency to 
differentiate to EC when compared with fibroblast derived iPSC.28, 33, 34 others showed similar or 
highly variable differentiation efficiency between these two groups.24, 43, 44 Obviously, more studies 
are needed to answer this question. 
 
The applications of hiPSC-EC 
EC derived from patient-specific hiPSC can provide a nearly limitless source of autologous cells 
for various applications against CVD. The most direct application of hiPSC-EC would be to 
provide these cells as a therapy to replace injured or dysfunctional EC present in the systemic 
vasculature. Indeed, in some cases, such as patients suffering critical limb ischemia (CLI), 
evidence has been presented that there is loss of the microvasculature and within isolated blood 
vascular EC from these patients, high proliferative ECFC are completely absent.42 It has been 
shown that hiPSC-EC from various protocols form functional blood vessels upon transplantation 
in a 3D gel matrix16, 19, 24, 25, 29, 34, 36, 38, 40-42, 47, 61, 68, 90 or into zebrafish embryos,43, 44 suggesting that  
hiPSC-EC display potential to treat CVD by directly forming vessels and improving blood 
perfusion. Some other cell types, like mesenchymal and hematopoietic lineage cells, can also 
promote blood vessel growth and improve blood perfusion through indirect mechanisms in these 
animal models41, 88, 90. However, these non-EC cell types generally do not integrate into the newly 
formed blood vessels as long-term components,89, 92, 93 thus as a potential cell therapy, repetitive 
delivery of these cells might be necessary. Likewise, though some recent evidence show that 
extracellular vesicles, like microvesicles and exosomes from different cell source could also 
promote angiogenesis,110, 111 their short-half life and low encytosis rate are potential hurdles for 
their clinical applications.110 In addition, all in-direct pro-angiogenic effects from these non-EC cell 
types or extracellular vesicles rely on the communication between these cells/vesicles and local 
EC in host vessels. Thus for those patients who suffer from diminished EC proliferative potential, 
like CLI patients,42 the therapeutic benefits of non-EC agents are unlikely to be effective. In 
contrast, hiPSC-EC have the potential to form stabilized functional vessels and thus provide long-
lasting support to the patients’ blood vessel system. Indeed, although to date, no clinical trail using 
hiPSC-EC on human CVD patients has been performed, the therapeutic potential of hiPSC-EC 
has already been tested in many pre-clinical animal studies including hind limb ischemia,22-24, 42, 
68, 69 myocardial infarction,24, 25, 51 retinopathy,34, 42 carotid artery injury26 and dermal wound healing 
models.16, 65, 72  In those studies, in situ administration of hiPSC-EC improved the recovery of 
model animals after injury and most reports16, 22-25, 34, 42, 51, 68, 69, 72 highlighted significant levels of 
integration of donor cells into the host vasculature after transplantation. Thus, patient subjects 
suffering from peripheral artery disease, delayed wound healing, acute and chronic heart failure, 
stroke, and certain forms of retinopathy that are associated with endothelial dysfunction and 
vascular dropout are prospective target groups to benefit from this form of cell therapy (Figure 3). 
Other than direct administration of EC suspensions, hiPSC-EC can also be mixed with 
other cell types in a 3D scaffold to assemble transplantable tissue grafts. Donor EC formed blood 
vessels can promote the connection of a graft into the host vascular system thus improving the 
survival of grafts after transplantation. To date, liver,46 cardiac10, 45, 53, 112 and skin grafts50 have 
been developed in vitro and transplanted into injured animals. In all these cases, the engrafted 
animals showed improved recovery and inosculated donor vessels.10, 45, 46, 50, 53, 112 In addition, Lu 
et al.39 have reported that decellularized murine heart scaffolds could be recellularized with hiPSC 
derived multipotent cardiovascular progenitors to engineer heart tissue with contractile function 
(Figure 3). Other than those tissue grafts, miniaturized organoids that mimics the structure and 
function of in vivo organs including blood vessel,113 kidney,114, 115 liver,116 cornea,117 and retina,118 
in 3D culture have also been constructed using hiPSC-EC and other cell types. These organoids 
can be potentially used for drug screening, disease study, or cell therapy as units of an artificial 
tissue graft.    
Patient-specific hiPSC-EC can also be potentially used for studying disease mechanisms 
or drug screening to find new molecules to modulate pathways contributing to endothelial 
dysfunction in a patient and disease specific fashion. Compared to animal models, models using 
patient derived hiPSC-EC may provide more human-relevant information on disease mechanisms 
or drug responses (Figure 3).  Recently, the pool of CVD patient specific hiPSC lines is expanding 
rapidly. Disease specific hiPSC-EC have been generated and studied to model BMPR2 mutation 
caused pulmonary arterial hypertension,119-121 Moyamoya disease,56, 58 fibrodysplasia ossificans 
progressiva,35 Huntington’s Disease,78 Kawasaki disease,109 type I diabetes,41, 57, 122 atrial or 
ventricular septal defects, pulmonary valve stenosis, cardiomyopathy,123 calcified aortic valve 
disease (CAVD),124 and Hemophilia A (HA).11 We have summarized above-mentioned disease 
studies that have characterized disease patient hiPSC derived EC in Table 1. For more 
information about patients derived hiPSC lines, please check International Stem Cell Registry 
(https://www.umassmed.edu/iscr) or CIRM human pluripotent stem cell registry 
(https://catalog.coriell.org/1/CIRM).  
Along with the development of advanced gene editing tools such as transcription activator-
like effector nucleases (TALEN) and CRISPR/Cas9, more and more new strategies using targeted 
gene correction to treat or study cardiovascular related diseases have been developed. To 
understand the effect of BMPR2 mutations in EC, Gu et al.121 compared EC differentiated from 
familial pulmonary arterial hypertension (FPAH) patient derived hiPSC, normal control patient 
derived hiPSC, unaffected BMPR2 mutation carrier patient derived hiPSC, and CRISPR/Cas9 
rescued FPAH patient derived hiPSC. EC differentiated from FPAH patient derived hiPSC with 
BMPR2 mutations possessed impaired EC functions and survival, while unaffected carrier patient 
hiPSC or BMPR2 rescued FPAH patient hiPSC derived EC were relatively normal, suggesting 
additional BMPR2 modifiers play a role for the protection of unaffected carriers from FPAH 
phenotype.121 Theodoris et al.124 compared gene expression and the epigenetic landscape 
between EC derived from CAVD patient iPSC with NOTCH 1 mutation and TALEN rescued 
isogenic iPSC and discovered NOTCH1 haploinsufficiency caused epigenetic changes that lead 
to the up-regulation of osteogenesis gene expression in CAVD patient EC.124 Yang et al.125 
surveyed the genome of patients with BAV and identified GATA4 as a target of mutation in these 
patients.125 EC differentiated from CRISPR/Cas9 induced GATA4 targeted mutation hiPSC were 
then used to confirm this mutation is associated with impaired endothelial to mesenchymal 
transition.125 Wu et al.11 have recently generated hiPSC lines from a patient with HA caused by a 
factor eight (FVIII) gene intron 22 inversion and used TALEN to correct this specific mutation. 
Corrected HA patient specific hiPSC-EC restored FVIII transcription and secretion.11  
As a platform for high-throughput drug screening and toxicity testing, hiPSC-EC can 
potentially be used to generate personalized therapeutic strategies. Recently, Vazao et al. 
developed a method to screen drugs that could potentially affect embryonic vasculature 
development and identified two drugs, fluphenazine and pyrrolopyrimidine, that could decrease 
EC viability and disrupted EC network formation.126 Sharma et al. generated hiPSC-EC as well 
as cardiomyocytes and fibroblasts from 11 healthy patients and 2 cancer patient to test the 
cardiotoxicity effect of 21 FDA approved anti-cancer tyrosine kinase inhibitors and developed a 
“cardiac safety index” for those drugs.127 To better mimic in vivo environments in which EC 
constantly undergo shear stress from blood flow and often interact with other local cell types, new 
microfluidic 3-D platforms like “organ-on-a chip” have been developed and tested for drug 
screening on various in vitro organ mimics.128, 129 Recently, Wang et al. developed an in vitro BBB 
microfluidic model using hiPSC-EC and validated the potential of this approach for screening 
drugs that affect EC permeability.130 As more sophisticated in vitro vascularized organ models are 
developed, it can be expected that pre-clinical drug development process for CVD can be greatly 
shortened.  
 
 Challenges for the applications of hiPSC-EC as cell therapy   
IPSC technology has only been developing as a discipline for a decade. Though hiPSC has been 
extensively applied for in vitro mechanistic studies, their application as cell therapy still face 
numerous practical problems, like low reprogramming efficiency,131 genetic instability,132-134 and 
potential of teratoma formation from undifferentiated iPSC.135 To date, only one clinical trial has 
been completed in human subjects, using hiPSC derived retinal pigment epithelial cells,136 and 
the safety and effectiveness of hiPSC therapy are still under evaluation. In general, application of 
hiPSC derived cells Cell therapy for CVD will require a large number of EC to replace the 
dysfunctional EC present in specific tissues and organs. However, most hiPSC-EC differentiation 
protocols that have been developed so far generate low EC yields and only produce mature EC 
with limited proliferative potential. Scaling-up the starting hiPSC cell number can partially solve 
this problem but may not be practical or cost-efficient. Recently several groups have started to 
focus on differentiating hiPSC into EC precursors that display high proliferative potential.25, 41, 42 It 
can be predicted that along with a better understanding of the mechanisms of EC lineage 
specification and proliferation, more efficient proliferative EC differentiation strategies should be 
developed to get clinical relevant numbers of hiPSC-EC for cell therapies.  
              The second limitation for current hiPSC-EC studies is the lack of a commonly-accepted 
standard to evaluate the quality of hiPSC-EC derived from various protocols to assess their 
potential for clinical use. While the route of delivery and the dose of cells to be used need to be 
determined case-by-case for each therapy, a basic set of quality control requirements for a hiPSC-
EC therapeutic should be discussed and evidence based. However, many in vitro assays that are 
frequently used to define the quality of the hiPSC-EC, like CD31 expression, LDL binding, or 2-D 
Matrigel network formation, cannot definitively predict the ability of the EC to form vessels in 
vivo.88, 89 Thus, to evaluate the quality of a hiPSC-EC product, some form of testing to validate in 
vivo vessel formation in animal models is recommended. 
          The next challenge for the practical utilization of hiPSC-EC is developing differentiation 
protocols that mimic the heterogeneous nature and tissue specificity of vascular EC. It is well 
known that arterial, venous, lymphatic and capillary EC show different patterns of gene expression 
and function.137-139 Additionally, EC from each organ vascular bed share some common features, 
but also show unique gene expression signatures.140 While most hiPSC-EC are not fully 
committed to any specific EC phenotype, several studies have attempted to induce hiPSC-EC to 
express tissue specific functions64, 73-87 or arterial/venous/lymphatic EC phenotypes.29, 31, 71, 72 For 
example, in vitro cultured ECFC, which mostly form capillary EC after transplantation, also 
possess the ability to differentiate into arterial EC in vivo when constitutively activated NOTCH 
expressing stromal cells are co-implanted.141 The local tissue microenvironment has been 
reported to “educate” murine ESC derived EC to adapt the gene expression pattern of tissue 
specific EC upon transplantation.140 Thus, some EC possess the capacity to adapt to local 
environmental cues in vivo and further work to develop similar responsive hiPSC-EC are 
underway. 
            Finally, although autologous patient derived hiPSC-EC are promising for the treatment of 
chronic CVD, the process of hiPSC induction and EC differentiation can take several months to 
complete, which makes their potential for treating acute injuries unlikely. Some investigators are 
directly reprogramming somatic cells into EC without a pluripotent intermediate.142-144 At present 
it is unclear if the reprogrammed EC possess high proliferative potential. As an alternative 
strategy, some investigators are proposing to use banked allogeneic haplotype-matched hiPSC 
to produce cell products to diminish the potential for immunologic detection and elimination.145 
Other strategies include development of hiPSC lines that are genome edited to make universal 
donor cells that lack major histocompatibility antigens I and II that should be immunologically well 
tolerated by the host unmatched patients.146-148 These strategies will be helpful in overcoming 
some of the practical issues for production of banks of hiPSC derived EC for cell therapy. 
 
Conclusions 
In the past decade, numerous methods to differentiate EC from hiPSC, have been developed 
and the potential of applying hiPSC-EC in regenerative medicine approaches have been tested 
in various animal models of human disease. In addition, many patient-specific hiPSC lines have 
been generated and EC differentiated from these lines have been used for disease mechanism 
exploration and discovery. The accumulating knowledge on hiPSC-EC differentiation, functional 
evaluation and potential application will benefit the development of new strategies against CVD. 
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Highlights 
• Numerous protocols have been developed to differentiate hiPSC into EC using stromal 
cell co-culture, embryoid body (3D) culture, or 2-D monolayer culture strategies. 
• The in vivo blood vessel forming potential and in vitro clonal proliferative potential should 
be assayed as a quality control measure before using hiPSC-EC for cell therapy. 
• HiPSC-EC can be employed in patients with cardiovascular disease through direct cell 
administration, implantation of engineered tissue grafts, or as models for studying the 
disease mechanisms causing EC dysfunction, or for drug screening.   
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Table 1. List of publications using patient derived hiPSC-EC for disease study   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure Legends 
 
Figure 1. General strategies for hiPSC-EC differentiation. 
 
Figure 2. General methods to evaluate the quality of hiPSC-EC. 
 
Figure 3. Potential applications of hiPSC-EC. 
 
Table 1. List of publications using patient derived hiPSC-EC for disease study   
 
Disease Mutation EC Phenotype Year Authors Reference 
Moyamoya disease RNF213 R4810K polymorphism 
-In vitro tube formation↓ 
-Securin expression↓ 2013 Hitomi et al. 56 
Pulmonary arterial hypertension (PAH) BMPR2 
-Differentiation↓ 
-LDL uptake↓ 
-In vitro tube formation↓ 
-Wnt signaling↑ 
2014 West et al. 119 
Type I diabetes (T1D) - -Differentiation no effect 2015 Chan et al. 57 
Calcified aortic valve disease (CAVD) NOTCH1 haploinsufficiency 
-Epigenetic architecture change 
- pro-osteogenic genes↑ 
-Inflammatory genes↑ 
2015 Theodoris et al. 124 
Hemophilia A (HA) FVIII intron 22 inversion -FVIII secretion↓ -FVIII activity↓ 2016 Wu et al. 11 
Fibrodysplasia ossificans progressiva (FOP) ACVR1 R206H 
-BMP4 independent differentiation 
-Fibroblast related gene 
expression↑ 
-BMP4 induced SMAD1/5/8 
phosphorylation↑ 
2016 Barruet et al. 35 
Moyamoya disease RNF213 R4810K 
-In vitro tube formation↓ 
-Proliferation no effect 
-Integrin β3 expression↓ 
2016 Hamauchi et al. 58 
Intravenous immunoglobulin (IVIG) resistant 
Kawasaki disease - 
-CXCL12 expression↑ 
-Interleukin-6 pathway↑  2016 Ikeda et al. 109 
Atrial or ventricular septal defects, pulmonary 
valve stenosis, cardiomyopathy GATA4 G29S -EC related gene expression↑ 2016 Ang et al. 121 
Huntington’s Disease (HD) CAG repeat expansion in Huntingtin (HTT) 
-In vitro tube formation↑ 
-Barrier function↓ 
- WNT/β-Catenin pathway↑ 
2017 Lim et al. 78 
Pulmonary arterial hypertension (PAH) - 
-In vitro tube formation↓ 
-Adhesison↓ 
-Migration↓ 
-Survival↓ 
-BMPR2 expression↓ 
-Kisspeptin 1 expression↑ 
2017 Sa. et al. 120 
Familial pulmonary arterial hypertension (FPAH) BMPR2 
-In vitro tube formation↓ 
-Adhesison↓ 
-Migration↓ 
-Survival↓ 
2017 Gu et al. 121 
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